SANA (MVD‑1)
Clinical-stage small molecule (Eolo Pharma, development code MVD1) that activates creatine-dependent thermogenesis (the 'futile creatine cycle' in thermogenic / beige fat), raising ENERGY EXPENDITURE rather than suppressing appetite like GLP-1 drugs. The 3 cited studies establish the PATHWAY, NOT SANA. Investigational, NOT approved.
WHAT IS SANA (MVD-1)?
Detailed overview
SANA (development code MVD1) is a clinical-stage small molecule candidate from Eolo Pharma that approaches obesity from a fundamentally different direction than today's appetite-suppressant drugs (GLP-1 receptor agonists and similar). Whereas those reduce intake, SANA aims to raise ENERGY EXPENDITURE by pharmacologically activating creatine-dependent thermogenesis (the so-called 'futile creatine cycle' in thermogenic, beige fat). It is described as the only small molecule in clinical development that specifically targets this mechanism, and Eolo Pharma has published first-in-human research on it. An IMPORTANT distinction: the creatine-thermogenesis pathway itself is validated biology (Kazak, Rahbani, Sun and colleagues), but the three studies cited below establish that PATHWAY, they are NOT clinical trials of SANA. SANA's own human data comes via Eolo Pharma's first-in-human program (mentioned as a program, with NO PMID invented for it here). Status: investigational, clinical-stage compound, NOT approved (neither FDA nor EMA), and not available on the open research-chemical market the way older compounds are. Human efficacy and safety are still emerging.
Mechanism
Activation of creatine-dependent thermogenesis ('futile creatine cycle') in thermogenic / beige fat – raises energy expenditure, NOT an appetite suppressant
Developer / code
Eolo Pharma; development code MVD1. Clinical-stage, first-in-human program published.
Half-life
NOT public (clinical-stage compound; human PK data not publicly available)
Onset
NOT publicly known (human efficacy still emerging in the first-in-human program)
Legal status
Investigational, NOT approved (neither FDA nor EMA). Not on the open research-chemical market the way older compounds are.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 6
- No published human side-effect profile: an investigational clinical-phase compound, so the specific nature and frequency of effects are unknown.
- Theoretical mechanism-based risk: raising thermogenesis (heat production) could in principle increase warmth sensation, sweating or alter resting metabolism, this is NOT confirmed human data.
- Unknown hepatic and renal impact: no public human liver or kidney safety data exists, clearance and organ burden are uncharacterized.
- Unknown cardiovascular and thermoregulatory effect: no public human PK/PD, so cardiac, blood-pressure and heat-regulation effects are unassessed.
- Unknown interaction and additive risk with other metabolism-activating agents (MOTS-c, BAM15, SLU-PP-915, ATX-304); no clinical data on combinations.
- Product-safety risk: SANA is not on the open market, so any product sold online as 'SANA' has unverifiable contents and is unreliable.
Contraindications · 6
- Human self-medication in general: an investigational, NOT approved (neither FDA nor EMA) compound with no approved human dose or protocol, use outside a supervised clinical trial is contraindicated.
- Pregnancy and breastfeeding: absolute contraindication, no human reproductive safety data.
- Known liver or kidney disease: human clearance and organ burden are unknown, contraindicated.
- Cardiovascular disease: no human cardiovascular safety data for an energy-expenditure-raising mechanism, contraindicated.
- Competitive athletes: the WADA 'S0 catch-all non-approved substance' category may potentially apply to a non-approved, investigational agent.
- Concurrent use with other metabolism-activating / thermogenic agents: additive and interaction effects are unknown, caution advised (relative contraindication).
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
A creatine-driven substrate cycle enhances energy expenditure and thermogenesis in beige fat
Kazak L, Chouchani ET, Jedrychowski MP, Erickson BK et al.
Creatine kinase B controls futile creatine cycling in thermogenic fat
Rahbani JF, Roesler A, Hussain MF, Samborska B et al.
Mitochondrial TNAP controls thermogenesis by hydrolysis of phosphocreatine
Sun Y, Rahbani JF, Jedrychowski MP, Riley CL et al.
Telegram
Have a question about SANA (MVD‑1)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.